Bruker Corporation (BRKR - Free Report) recently announced preliminary revenues for first-quarter 2021. The company expects to release detailed financial results for the period on May 5.
As per the preliminary report, first-quarter 2021 revenues are estimated to be in the range of $549-$554 million on a reported basis, up by around 30-31% from the year-ago quarter. The Zacks Consensus Estimate of $508.8 million remains below the preliminary figure.
Bruker expects its first-quarter 2021 organic revenues (adjusted for the impacts of foreign currency translation and acquisitions) to grow by about 22-23% year over year, which is in line with the company’s expectation (to be above 15%) as provided in its last-reported quarter’s earnings call.
Per the company, the strong revenue uptick in the first quarter resulted from a double-digit organic year-over-year revenue growth across all three Bruker Scientific Instrument or BSI groups, including the two GHz-class Nuclear Magnetic Resonance (“NMR”) systems.
Following this after-market release yesterday, shares of the company are up 1.5% in today’s premarket trading.
2021 Financial Outlook
Bruker did not provide any yearly financial guidance in its first-quarter 2021 preliminary revenues press release. Nonetheless, the company, during its fourth-quarter 2020 earnings release in February, had initiated the financial outlook for the full-year 2021. The company expects full-year 2021 revenue growth in the band of 11-13% and organic revenue growth of approximately 7-9%. The Zacks Consensus Estimate for the full-year reported revenues is currently pegged at $2.24 billion.
The company projects its full-year adjusted earnings per share to lie in the range of $1.72-$1.77, reflecting an uptick of around 27-31% from the prior-year quarter. The Zacks Consensus Estimate for the same is currently pegged at $1.77.
A Brief Q1 Analysis
Bruker has been observing a robust adoption of its products by research entities over the past few months. The company, in January, announced that three institutions are now accelerating their research into functional structural biology and human disease with new ultra-high field NMR spectrometers installed in 2020. The same month, Bruker announced receipt of the FDA’s clearance and U.S. launch of the MBT Sepsityper Kit US IVD for rapid microbial identification of more than 425 microorganisms from positive blood cultures on the MALDI Biotyper CA System.
Meanwhile, the company’s preliminary projection of a robust improvement in revenues compared to the sequentially last-reported quarter, lifts our confidence.
Price Performance
Shares of the company have gained 16.8% in the past three months compared with the industry’s 4.2% growth and the S&P 500’s 10.6% rise.
Zacks Rank & Key Picks
Currently, Bruker carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AmerisourceBergen Corporation , Cantel Medical Corp. and DENTSPLY SIRONA Inc. (XRAY - Free Report) .
AmerisourceBergen’s long-term earnings growth rate is estimated at 11.4%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cantel’s long-term earnings growth rate is estimated at 19%. It currently carries a Zacks Rank #2.
DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Bruker Corporation (BRKR - Free Report) recently announced preliminary revenues for first-quarter 2021. The company expects to release detailed financial results for the period on May 5.
As per the preliminary report, first-quarter 2021 revenues are estimated to be in the range of $549-$554 million on a reported basis, up by around 30-31% from the year-ago quarter. The Zacks Consensus Estimate of $508.8 million remains below the preliminary figure.
Bruker expects its first-quarter 2021 organic revenues (adjusted for the impacts of foreign currency translation and acquisitions) to grow by about 22-23% year over year, which is in line with the company’s expectation (to be above 15%) as provided in its last-reported quarter’s earnings call.
Per the company, the strong revenue uptick in the first quarter resulted from a double-digit organic year-over-year revenue growth across all three Bruker Scientific Instrument or BSI groups, including the two GHz-class Nuclear Magnetic Resonance (“NMR”) systems.
Following this after-market release yesterday, shares of the company are up 1.5% in today’s premarket trading.
2021 Financial Outlook
Bruker did not provide any yearly financial guidance in its first-quarter 2021 preliminary revenues press release. Nonetheless, the company, during its fourth-quarter 2020 earnings release in February, had initiated the financial outlook for the full-year 2021. The company expects full-year 2021 revenue growth in the band of 11-13% and organic revenue growth of approximately 7-9%. The Zacks Consensus Estimate for the full-year reported revenues is currently pegged at $2.24 billion.
The company projects its full-year adjusted earnings per share to lie in the range of $1.72-$1.77, reflecting an uptick of around 27-31% from the prior-year quarter. The Zacks Consensus Estimate for the same is currently pegged at $1.77.
A Brief Q1 Analysis
Bruker has been observing a robust adoption of its products by research entities over the past few months. The company, in January, announced that three institutions are now accelerating their research into functional structural biology and human disease with new ultra-high field NMR spectrometers installed in 2020. The same month, Bruker announced receipt of the FDA’s clearance and U.S. launch of the MBT Sepsityper Kit US IVD for rapid microbial identification of more than 425 microorganisms from positive blood cultures on the MALDI Biotyper CA System.
Meanwhile, the company’s preliminary projection of a robust improvement in revenues compared to the sequentially last-reported quarter, lifts our confidence.
Price Performance
Shares of the company have gained 16.8% in the past three months compared with the industry’s 4.2% growth and the S&P 500’s 10.6% rise.
Zacks Rank & Key Picks
Currently, Bruker carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AmerisourceBergen Corporation , Cantel Medical Corp. and DENTSPLY SIRONA Inc. (XRAY - Free Report) .
AmerisourceBergen’s long-term earnings growth rate is estimated at 11.4%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cantel’s long-term earnings growth rate is estimated at 19%. It currently carries a Zacks Rank #2.
DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on XRAY - FREE
Get the latest research report on BRKR - FREE